297 filings
8-K
AERI
Aerie Pharmaceuticals Inc
21 Nov 22
Entry into a Material Definitive Agreement
10:01am
8-K
AERI
Aerie Pharmaceuticals Inc
18 Nov 22
Submission of Matters to a Vote of Security Holders
4:55pm
8-K
AERI
Aerie Pharmaceuticals Inc
7 Nov 22
Other Events
9:20am
8-K
AERI
Aerie Pharmaceuticals Inc
3 Nov 22
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
4:07pm
8-K
AERI
Aerie Pharmaceuticals Inc
13 Sep 22
Regulation FD Disclosure
4:01pm
8-K
ynyxdjwerf4g8n4
23 Aug 22
Entry into a Material Definitive Agreement
5:13pm
8-K
i1jt tgm701fsf9qjnp
22 Aug 22
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
9:37pm
8-K
jg3t702ua5us i7
4 Aug 22
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
5:40pm
8-K
8a7uaxboxi9m0oh7
1 Aug 22
Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease
4:21pm
8-K
5y0y3z69hs dx3
13 Jun 22
Submission of Matters to a Vote of Security Holders
4:09pm
8-K
jd22ne go
8 Jun 22
Regulation FD Disclosure
7:31am
8-K
f0f0d8qh6b8 qs9
25 May 22
Regulation FD Disclosure
7:31am
8-K
nov2hdy qkv83ewfdq
24 May 22
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
7:30am
8-K
jjunfv5 l8zauvabi5
5 May 22
Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
12:00am
8-K
5fbuf
11 Apr 22
Regulation FD Disclosure
6:19am
8-K
s1yywnh
18 Mar 22
Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer
8:06am
8-K
0k9scfi bd332hdlfu
4 Mar 22
Departure of Directors or Certain Officers
4:55pm
8-K
is1a8qcdjwwd
2 Mar 22
Departure of Directors or Certain Officers
8:31am
8-K
zokbi6pr
24 Feb 22
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
4:16pm
8-K
akoknua
25 Jan 22
Departure of Directors or Certain Officers
12:00am